225 results on '"Stehouwer, Coen D. A."'
Search Results
2. On the Interplay of Microvasculature, Parenchyma, and Memory in Type 2 Diabetes
- Author
-
van Bussel, Frank C., Backes, Walter H., Hofman, Paul A., van Oostenbrugge, Robert J., Kessels, Alfons G., van Boxtel, Martin P., Schram, Miranda T., Stehouwer, Coen D., Wildberger, Joachim E., and Jansen, Jacobus F.
- Published
- 2015
- Full Text
- View/download PDF
3. NH2-Terminal Probrain Natriuretic Peptide Is Associated With Diabetes Complications in the EURODIAB Prospective Complications Study: The role of tumor necrosis factor-α
- Author
-
Gruden, Gabriella, Barutta, Federica, Chaturvedi, Nish, Schalkwijk, Casper, Stehouwer, Coen D., Pinach, Silvia, Manzo, Maria, Loiacono, Maria, Tricarico, Marinella, Mengozzi, Giulio, Witte, Daniel R., Fuller, John H., Perin, Paolo Cavallo, and Bruno, Graziella
- Published
- 2012
- Full Text
- View/download PDF
4. Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study
- Author
-
Gruden, Gabriella, Barutta, Federica, Chaturvedi, Nish, Schalkwijk, Casper, Stehouwer, Coen D., Witte, Daniel R., Fuller, John H., Cavallo Perin, Paolo, and Bruno, Graziella
- Published
- 2012
- Full Text
- View/download PDF
5. Independent Associations of Glucose Status and Arterial Stiffness With Left Ventricular Diastolic Dysfunction: An 8-year follow-up of the Hoorn Study
- Author
-
van den Hurk, Katja, Alssema, Marjan, Kamp, Otto, Henry, Ronald M., Stehouwer, Coen D., Smulders, Yvo M., Nijpels, Giel, Paulus, Walter J., and Dekker, Jacqueline M.
- Published
- 2012
- Full Text
- View/download PDF
6. N[H.sub.2]-terminal probrain natriuretic peptide is associated with diabetes complications in the EURODIAB prospective complications study: the role of tumor necrosis factor-[alpha]
- Author
-
Gruden, Gabriella, Barutta, Federica, Chaturvedi, Nish, Schalkwijk, Casper, Stehouwer, Coen D., Pinach, Silvia, Manzo, Maria, Loiacono, Maria, Tricarico, Marinella, Mengozzi, Giulio, Witte, Daniel R., Fuller, John H., Perin, Paolo Cavallo, and Bruno, Graziella
- Subjects
Tumors -- Complications and side effects -- Research ,Type 1 diabetes -- Complications and side effects -- Research ,Diabetes -- Research ,Natriuretic peptides ,Tumor necrosis factor ,Cardiovascular diseases -- Complications and side effects -- Research ,Health - Abstract
OBJECTIVE--Circulating levels of N[H.sub.2]-terminal probrain natriuretic peptide (NT-proBNP), a marker of acute heart failure, are associated with increased risk of cardiovascular disease (CVD) in the general population. However, there is [...]
- Published
- 2012
- Full Text
- View/download PDF
7. Meal-Related Increases in Microvascular Vasomotion Are Impaired in Obese Individuals: A potential mechanism in the pathogenesis of obesity-related insulin resistance
- Author
-
Jonk, Amy M., Houben, Alfons J., Schaper, Nicolaas C., de Leeuw, Peter W., Serné, Erik H., Smulders, Yvo M., and Stehouwer, Coen D.
- Published
- 2011
- Full Text
- View/download PDF
8. Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
- Author
-
Nin, Johanna W., Jorsal, Anders, Ferreira, Isabel, Schalkwijk, Casper G., Prins, Martin H., Parving, Hans-Henrik, Tarnow, Lise, Rossing, Peter, and Stehouwer, Coen D.
- Published
- 2011
- Full Text
- View/download PDF
9. Anti–Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study
- Author
-
Burt, Davina, Bruno, Graziella, Chaturvedi, Nish, Schalkwijk, Casper, Stehouwer, Coen D., Witte, Daniel R., Fuller, John H., Pinach, Silvia, Cavallo Perin, Paolo, and Gruden, Gabriella
- Published
- 2009
10. Diabetes-Related Symptom Distress in Association With Glucose Metabolism and Comorbidity: The Hoorn Study
- Author
-
Adriaanse, Marcel C., Pouwer, Frans, Dekker, Jacqueline M., Nijpels, Giel, Stehouwer, Coen D., Heine, Robert J., and Snoek, Frank J.
- Published
- 2008
11. Exercise Training Improves Glycemic Control in Long-Standing Insulin-Treated Type 2 Diabetic Patients
- Author
-
DE FEYTER, HENK M., PRAET, STEPHAN F., VAN DEN BROEK, NICOLE M., KUIPERS, HARM, STEHOUWER, COEN D., NICOLAY, KLAAS, PROMPERS, JEANINE J., and VAN LOON, LUC J.C.
- Published
- 2007
12. Vascular Risk Factors and Markers of Endothelial Function as Determinants of Inflammatory Markers in Type 1 Diabetes: The EURODIAB Prospective Complications Study
- Author
-
Schram, Miranda T., Chaturvedi, Nish, Schalkwijk, Casper, Giorgino, Francesco, Ebeling, Pertti, Fuller, John H., and Stehouwer, Coen D.
- Published
- 2003
13. Leptin and Variables of Body Adiposity, Energy Balance, and Insulin Resistance in a Population-Based Study: The Hoorn Study
- Author
-
Ruige, Johannes B., Dekker, Jacqueline M., Blum, Werner F., Stehouwer, Coen D. A., Nijpels, Giel, Mooy, Joke, Kostense, Pieter J., Bouter, Lex M., and Heine, Robert J.
- Published
- 1999
14. Fasting and Post-Methionine Homocysteine Levels in NIDDM: Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease
- Author
-
Smulders, Yvo M., Rakic, Melina, Slaats, H., Treskes, Marco, Sijbrands, Eric J. G., Odekerken, Diego A. M., Stehouwer, Coen D. A., and Silberbusch, Joseph
- Published
- 1999
15. White Matter Connectivity Abnormalities in Prediabetes and Type 2 Diabetes: The Maastricht Study
- Author
-
Vergoossen, Laura W., primary, Schram, Miranda T., additional, de Jong, Joost J., additional, Stehouwer, Coen D., additional, Schaper, Nicolaas C., additional, Henry, Ronald M., additional, van der Kallen, Carla J., additional, Dagnelie, Pieter C., additional, van Boxtel, Martin P., additional, Eussen, Simone J., additional, Backes, Walter H., additional, and Jansen, Jacobus F., additional
- Published
- 2019
- Full Text
- View/download PDF
16. The 1997 American Diabetes Association Criteria Versus the 1985 World Health Organization Criteria for the Diagnosis of Abnormal Glucose Tolerance: Poor agreement in the Hoorn Study
- Author
-
de Vegt, Femmie, Dekker, Jacqueline M., Stehouwer, Coen D. A., Nijpels, Giel, Bouter, Lex M., and Heine, Robert J.
- Published
- 1998
17. Carotid Artery Stiffness Is Increased in Microalbuminuric IDDM Patients
- Author
-
Lambert, Jan, Smulders, Ronald A., Aarsen, Mieke, Donker, Ab, and Stehouwer, Coen D. A.
- Published
- 1998
18. Determinants of Progression of Microalbuminuria in Patients With NIDDM: A prospective study
- Author
-
Smulders, Yvo M., Rakic, Melina, Stehouwer, Coen D. A., Weijers, Rob N. M., Slaats, H., and Silberbusch, Joseph
- Published
- 1997
19. Vessel Wall Properties of Large Arteries in Uncomplicated IDDM
- Author
-
Kool, Mirian J., Lambert, Jan, Stehouwer, Coen D., Hoeks, Arnold P., Struijker Boudier, Harry A., and Van Bortel, Luc M.
- Published
- 1995
20. White Matter Connectivity Abnormalities in Prediabetes and Type 2 Diabetes: The Maastricht Study.
- Author
-
Vergoossen, Laura W., Schram, Miranda T., de Jong, Joost J., Stehouwer, Coen D., Schaper, Nicolaas C., Henry, Ronald M., van der Kallen, Carla J., Dagnelie, Pieter C., van Boxtel, Martin P., Eussen, Simone J., Backes, Walter H., and Jansen, Jacobus F.
- Abstract
Objective: Prediabetes and type 2 diabetes are associated with structural brain abnormalities, often observed in cognitive disorders. Besides visible lesions, (pre)diabetes might also be associated with alterations of the intrinsic organization of the white matter. In this population-based cohort study, the association of prediabetes and type 2 diabetes with white matter network organization was assessed.Research Design and Methods: In the Maastricht Study, a type 2 diabetes-enriched population-based cohort study (1,361 subjects with normal glucose metabolism, 348 with prediabetes, and 510 with type 2 diabetes assessed by oral glucose tolerance test; 52% men; aged 59 ± 8 years), 3 Tesla structural and diffusion MRI was performed. Whole-brain white matter tractography was used to assess the number of connections (node degree) between 94 brain regions and the topology (graph measures). Multivariable linear regression analyses were used to investigate the associations of glucose metabolism status with network measures. Associations were adjusted for age, sex, education, and cardiovascular risk factors.Results: Prediabetes and type 2 diabetes were associated with lower node degree after full adjustment (standardized [st]βPrediabetes = -0.055 [95% CI -0.172, 0.062], stβType2diabetes = -0.256 [-0.379, -0.133], Ptrend < 0.001). Prediabetes was associated with lower local efficiency (stβ = -0.084 [95% CI -0.159, -0.008], P = 0.033) and lower clustering coefficient (stβ = -0.097 [95% CI -0.189, -0.005], P = 0.049), whereas type 2 diabetes was not. Type 2 diabetes was associated with higher communicability (stβ = 0.148 [95% CI 0.042, 0.253], P = 0.008).Conclusions: These findings indicate that prediabetes and type 2 diabetes are associated with fewer white matter connections and weaker organization of white matter networks. Type 2 diabetes was associated with higher communicability, which was not yet observed in prediabetes and may reflect the use of alternative white matter connections. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study.
- Author
-
van Agtmaal, Marnix J. M., Houben, Alfons J. H. M., de Wit, Vera, Henry, Ronald M. A., Schaper, Nicolaas C., Dagnelie, Pieter C., van der Kallen, Carla J., Koster, Annemarie, Sep, Simone J., Kroon, Abraham A., Jansent, Jacobus F. A., Hofman, Paul A., Backesf, Walter H., Schram, Miranda T., Stehouwer, Coen D. A., Jansen, Jacobus F A, and Backes, Walter H
- Subjects
BRAIN imaging ,MAGNETIC resonance imaging ,DIABETES ,CARDIOVASCULAR diseases ,TYPE 2 diabetes - Abstract
Objective: Structural brain abnormalities are key risk factors for brain diseases, such as dementia, stroke, and depression, in type 2 diabetes. It is unknown whether structural brain abnormalities already occur in prediabetes. Therefore, we investigated whether both prediabetes and type 2 diabetes are associated with lacunar infarcts (LIs), white matter hyperintensities (WMHs), cerebral microbleeds (CMBs), and brain atrophy.Research Design and Methods: We used data from 2,228 participants (1,373 with normal glucose metabolism [NGM], 347 with prediabetes, and 508 with type 2 diabetes (oversampled); mean age 59.2 ± 8.2 years; 48.3% women) of the Maastricht Study, a population-based cohort study. Diabetes status was determined with an oral glucose tolerance test. Brain imaging was performed with 3 Tesla MRI. Results were analyzed with multivariable logistic and linear regression analyses.Results: Prediabetes and type 2 diabetes were associated with the presence of LIs (odds ratio 1.61 [95% CI 0.98-2.63] and 1.67 [1.04-2.68], respectively; Ptrend = 0.027), larger WMH (β 0.07 log10-transformed mL [log-mL] [95% CI 0.00-0.15] and 0.21 log-mL [0.14-0.28], respectively; Ptrend <0.001), and smaller white matter volumes (β -4.0 mL [-7.3 to -0.6] and -7.2 mL [-10.4 to -4.0], respectively; Ptrend <0.001) compared with NGM. Prediabetes was not associated with gray matter volumes or the presence of CMBs.Conclusions: Prediabetes is associated with structural brain abnormalities, with further deterioration in type 2 diabetes. These results indicate that, in middle-aged populations, structural brain abnormalities already occur in prediabetes, which may suggest that the treatment of early dysglycemia may contribute to the prevention of brain diseases. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. High Diabetes Distress Among Ethnic Minorities Is Not Explained by Metabolic, Cardiovascular, or Lifestyle Factors: Findings From the Dutch Diabetes Pearl Cohort.
- Author
-
Özcan, Behiye, Rutters, Femke, Snoek, Frank J., Roosendaal, Mandy, Sijbrands, Eric J., Elders, Petra J. M., Holleman, Frits, Pijl, Hanno, Tack, Cees J., Abbink, Evertine J., de Valk, Harold W., Wolffenbuttel, Bruce H. R., Stehouwer, Coen D. A., Schaper, Nicholas C., Dekker, Jacqueline M., Schram, Miranda T., and Diabetes Pearl from the Parelsnoer Initiative
- Subjects
TYPE 2 diabetes & psychology ,STATISTICS on minorities ,TYPE 2 diabetes complications ,BLOOD sugar ,CARDIOVASCULAR diseases ,COMPARATIVE studies ,DIABETIC angiopathies ,ETHNIC groups ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,TYPE 2 diabetes ,RESEARCH ,PSYCHOLOGICAL stress ,WHITE people ,EVALUATION research ,LIFESTYLES ,DISEASE prevalence ,CROSS-sectional method ,DISEASE complications ,PSYCHOLOGY - Abstract
Objective: Diabetes distress among patients from ethnic minorities is still poorly understood. We investigated the association between ethnicity and diabetes distress among ethnic minority groups of people with type 2 diabetes in the Netherlands, focusing on the possible effects of glycemic control, lifestyle factors, cardiovascular risk factors, and diabetes complications.Research Design and Methods: Cross-sectional data from the Dutch Diabetes Pearl cohort included people with type 2 diabetes from primary, secondary, and tertiary diabetes care programs. We used the 20-item Problem Areas in Diabetes Survey (PAID) scale to assess diabetes distress; a score ≥40 is considered to represent high distress. Ethnicity was estimated on the basis of country of birth. Sociodemographic and lifestyle data were self-reported; cardiovascular and metabolic data were retrieved from medical charts. Logistic regression analysis determined the association between ethnicity and diabetes distress, with Caucasians as the reference group.Results: Diabetes distress scores and ethnicity were available for 4,191 people with type 2 diabetes: 3,684 were Caucasian, 83 were Asian, 51 were Moroccan, 92 were African, 134 were Latin American, 46 were Turkish, and 101 were Hindustani-Surinamese. Overall, participants in minority groups had worse health outcomes than those of Caucasian descent, and diabetes distress was more prevalent (ranging from 9.6 to 31.7%, compared with 5.8% among Caucasians), even after adjusting for age, sex, education level, alcohol use, smoking, BMI, lipid profile, HbA1c, medication use, and the presence of diabetes complications.Conclusions: Among people with type 2 diabetes in the Netherlands, ethnicity is independently associated with high diabetes distress. Further research is warranted to explain the higher prevalence of diabetes distress in minority groups and to develop effective interventions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes.
- Author
-
Hanssen, Nordin M. J., Westerink, Jan, Scheijen, Jean L. J. M., van der Graaf, Yolanda, Stehouwer, Coen D. A., Schalkwijk, Casper G., and SMART Study Group
- Subjects
PEOPLE with diabetes ,PYRUVALDEHYDE ,CARDIOVASCULAR disease related mortality ,CARDIOVASCULAR diseases ,CARDIOVASCULAR diseases risk factors ,GENETICS ,PHYSIOLOGY ,MYOCARDIAL infarction complications ,TYPE 2 diabetes complications ,ALDEHYDES ,COMPARATIVE studies ,DIABETIC angiopathies ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,MORTALITY ,MYOCARDIAL infarction ,TYPE 2 diabetes ,RESEARCH ,SURVIVAL analysis (Biometry) ,EVALUATION research ,DISEASE incidence - Abstract
Objective: Methylglyoxal (MGO) is a reactive dicarbonyl compound and a potential key player in diabetic cardiovascular disease (CVD). Whether plasma MGO levels are associated with CVD in type 2 diabetes is unknown.Research Design and Methods: We included 1,003 individuals (mean ± SD age 59.1 ± 10.5 years, 69.3% male, and 61.6% with prior CVD) with type 2 diabetes from the Second Manifestations of ARTerial disease cohort (SMART). We measured plasma MGO levels and two other dicarbonyls (glyoxal [GO] and 3-deoxyglucosone [3-DG]) at baseline with mass spectrometry. Median follow-up of CVD events was 8.6 years. Data were analyzed with Cox regression with adjustment for sex, age, smoking, systolic blood pressure, total cholesterol, HbA1c, BMI, prior CVD, and medication use. Hazard ratios are expressed per SD Ln-transformed dicarbonyl.Results: A total of 287 individuals suffered from at least one CVD event (n = 194 fatal events, n = 146 myocardial infarctions, and n = 72 strokes); 346 individuals died, and 60 individuals underwent an amputation. Higher MGO levels were associated with total (hazard ratio 1.26 [95% CI 1.11-1.42]) and fatal (1.49 [1.30-1.71]) CVD and with all-cause mortality (1.25 [1.11-1.40]), myocardial infarction (1.22 [1.02-1.45]), and amputations (1.36 [1.05-1.76]). MGO levels were not apparently associated with stroke (1.03 [0.79-1.35]). Higher GO levels were significantly associated with fatal CVD (1.17 [1.00-1.37]) but not with other outcomes. 3-DG was not significantly associated with any of the outcomes.Conclusions: Plasma MGO and GO levels are associated with cardiovascular mortality in individuals with type 2 diabetes. Influencing dicaronyl levels may therefore be a target to reduce CVD in type 2 diabetes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. Social Network Characteristics Are Associated With Type 2 Diabetes Complications: The Maastricht Study.
- Author
-
Brinkhues, Stephanie, Dukers-Muijrers, Nicole H. T. M., Hoebe, Christian J. P. A., Van Der Kallen, Carla J. H., Koster, Annemarie, Henry, Ronald M. A., Stehouwer, Coen D. A., Savelkoul, Paul H. M., Schaper, Nicolaas C., and Schram, Miranda T.
- Subjects
PEOPLE with diabetes ,PATIENTS -- Social aspects ,SOCIAL networks ,DIABETES complications ,QUALITY of life ,SOCIAL history - Abstract
Objective: The relation between clinical complications and social network characteristics in type 2 diabetes mellitus (T2DM) has hardly been studied. Therefore, we examined the associations of social network characteristics with macro- and microvascular complications in T2DM and investigated whether these associations were independent of glycemic control, quality of life, and well-known cardiovascular risk factors.Research Design and Methods: Participants with T2DM originated from the Maastricht Study, a population-based cohort study (n = 797, mean age 62.7 ± 7.6 years, 31% female). Social network characteristics were assessed through a name generator questionnaire. Diabetes status was determined by an oral glucose tolerance test. Macro- and microvascular complications were defined as a history of cardiovascular disease and the presence of impaired vibratory sense and/or retinopathy and/or albuminuria, respectively. We assessed cross-sectional associations of social network characteristics with macro- and microvascular complications by use of logistic regression adjusted for age, HbA1c, quality of life, and cardiovascular risk factors, stratified for sex.Results: A smaller network size, higher percentages of family members, and lower percentages of friends were independently associated with macrovascular complications in both men and women. A smaller network size and less informational support were independently associated with microvascular complications in women, but not in men.Conclusions: This study shows that social network characteristics were associated with macro- and microvascular complications. Health care professionals should be aware of the association of the social network with T2DM outcomes. In the development of strategies to reduce the burden of disease, social network characteristics should be taken into account. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance-The Maastricht Study.
- Author
-
Geijselaers, Stefan L. C., Sep, Simone J. S., Claessens, Danny, Schram, Miranda T., van Boxte, Martin P. J., Henry, Ronald M. A., Verhey, Frans R. J., Kroon, Abraham A., Dagnelie, Pieter C., Schalkwijk, Casper G., van der Kallen, Carla J. H., Biessels, Geert Jan, and Stehouwer, Coen D. A.
- Subjects
GLUCOSE metabolism ,HYPERGLYCEMIA ,INSULIN resistance ,BLOOD pressure ,GLYCOSYLATED hemoglobin ,DIABETES prevention - Abstract
Objective: To study to what extent differences in cognitive performance between individuals with different glucose metabolism status are potentially attributable to hyperglycemia, insulin resistance, and blood pressure-related variables.Research Design and Methods: We used cross-sectional data from 2,531 participants from the Maastricht Study (mean age ± SD, 60 ± 8 years; 52% men; n = 666 with type 2 diabetes), all of whom completed a neuropsychological test battery. Hyperglycemia was assessed by a composite index of fasting glucose, postload glucose, glycated hemoglobin (HbA1c), and tissue advanced glycation end products; insulin resistance by the HOMA of insulin resistance index; and blood pressure-related variables included 24-h ambulatory pressures, their weighted SDs, and the use of antihypertensive medication. Linear regression analyses were used to estimate mediating effects.Results: After adjustment for age, sex, and education, individuals with type 2 diabetes, compared with those with normal glucose metabolism, performed worse in all cognitive domains (mean differences in composite z scores for memory -0.087, processing speed -0.196, executive function and attention -0.182; P values <0.032), whereas individuals with prediabetes did not. Diabetes-associated differences in processing speed and executive function and attention were largely explained by hyperglycemia (mediating effect 79.6% [bootstrapped 95% CI 36.6; 123.4] and 50.3% [0.6; 101.2], respectively) and, for processing speed, to a lesser extent by blood pressure-related variables (17.7% [5.6; 30.1]), but not by insulin resistance. None of the factors explained the differences in memory function.Conclusions: Our cross-sectional data suggest that early glycemic and blood pressure control, perhaps even in the prediabetic stage, may be promising therapeutic targets for the prevention of diabetes-associated decrements in cognitive performance. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
26. A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies.
- Author
-
Simons, Nynke, Dekker, Jacqueline M., van Greevenbroek, Marleen M. J., Nijpels, Giel, 't Hart, Leen M., van der Kallen, Carla J. H., Schalkwijk, Casper G., Schaper, Nicolaas C., Stehouwer, Coen D. A., and Brouwers, Martijn C. G. J.
- Subjects
TYPE 2 diabetes ,GLUCOKINASE ,DYSLIPIDEMIA ,ATHEROSCLEROSIS ,TRIGLYCERIDES ,ALLELES ,BLOOD sugar ,BODY weight ,CARRIER proteins ,GENETICS ,GLYCOSYLATED hemoglobin ,HIGH density lipoproteins ,HYPERLIPIDEMIA ,LIVER ,LONGITUDINAL method ,LOW density lipoproteins ,REGRESSION analysis ,TRANSFERASES ,BODY mass index ,WAIST circumference - Abstract
Objective: Small molecules that disrupt the binding between glucokinase and glucokinase regulatory protein (GKRP) are potential new glucose-lowering targets. They stimulate hepatic glucose disposal by increasing glucokinase activity in the liver. It can, however, be anticipated that increased hepatic glucokinase activity might be accompanied by the development of hypertriglyceridemia, particularly in type 2 diabetes. We examined whether the strength of association between rs1260326, a common, functional gene variant in GKRP, and plasma lipids is affected by glucose metabolism.Research Design and Methods: rs1260326 was genotyped in subjects with normal glucose metabolism (n = 497), subjects with impaired glucose metabolism (n = 256), and patients with type 2 diabetes (n = 351) in the combined Hoorn and Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) studies.Results: The strength of association between the rs1260326 minor T allele and plasma triglycerides increased from normal glucose metabolism to impaired glucose metabolism to type 2 diabetes (P for interaction = 0.002). The inverse relation between rs1260326 and plasma HDL cholesterol was again most prominent in type 2 diabetes (P for interaction = 0.004). Similar trends were observed when the Hoorn and CODAM cohorts were analyzed separately. Comparable results were obtained when glucose metabolism strata were replaced by continuous indices of glucose metabolism, i.e., HbA1c and fasting plasma glucose.Conclusions: These findings illustrate that common gene variants, such as rs1260326, can have substantial effect sizes when they are studied in specific populations, such as type 2 diabetes. Moreover, our results shed light on potential side effects of small molecule disruptors of the GKRP-glucokinase complex, especially when glucose control is suboptimal. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. Both Low and High 24-Hour Diastolic Blood Pressure Are Associated With Worse Cognitive Performance in Type 2 Diabetes: The Maastricht Study.
- Author
-
Spauwen, Peggy J. J., van Boxtel, Martin P. J., Verhey, Frans R. J., Köhler, Sebastian, Sep, Simone J. S., Koster, Annemarie, Dagnelie, Pieter C., Henry, Ronald M. A., Schaper, Nicolaas C., van der Kallen, Carla J. H., Schram, Miranda T., Kroon, Abraham A., and Stehouwer, Coen D. A.
- Subjects
BLOOD pressure ,COGNITION disorder risk factors ,PEOPLE with diabetes ,COGNITIVE ability ,HUMAN information processing - Abstract
OBJECTIVE Hypertension and diabetes are both risk factors for cognitive decline, and individuals with both might have an especially high risk. We therefore examined linear and nonlinear (quadratic) associations of 24-h blood pressure (BP) with cognitive performance in participants with and without type 2 diabetes. We also tested the association of nocturnal dipping status with cognitive performance. RESEARCH DESIGN AND METHODS This study was performed as part of the Maastricht Study, an ongoing population- based cohort study. Cross-sectional associations of 24-h BP (n = 713, of whom 201 had type 2 diabetes) and nocturnal dipping status (n = 686, of whom 196 had type 2 diabetes) with performance on tests for global cognitive functioning, information processing speed, verbal memory (immediate and delayed word recall), and response inhibition were tested using linear regression analysis and adjusted for demographics, vascular risk factors, cardiovascular disease, depression, and lipid-modifying and antihypertensive medication use. RESULTS After full adjustment, we found quadratic (inverted U-shaped) associations of 24-h diastolic blood pressure (DBP) with information processing speed (b for quadratic term = -20.0267, P < 0.01) and memory (immediate word recall: b = -0.0180, P < 0.05; delayed word recall: b = -0.0076, P < 0.01) in participants with diabetes, but not in those without. No clear pattern was found for dipping status. CONCLUSIONS This study shows that both low and high 24-h DBP are associated with poorer performance on tests of information processing speed and memory in individuals with type 2 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Hyperglycemia Is the Main Mediator of Prediabetes- and Type 2 Diabetes-Associated Impairment of Microvascular Function: The Maastricht Study.
- Author
-
Sörensen, Ben M., Houben, Alfons J. H. M., Berendschot, Tos T. J. M., Schouten, Jan S. A. G., Kroon, Abraham A., Van Der Kallen, Carla J. H., Henry, Ronald M. A., Koster, Annemarie, Reesink, Koen D., Dagnelie, Pieter C., Schaper, Nicolaas C., Schalkwijk, Casper G., Schram, Miranda T., and Stehouwer, Coen D. A.
- Subjects
HYPERGLYCEMIA ,PREDIABETIC state ,TYPE 2 diabetes ,INSULIN resistance ,BLOOD pressure - Abstract
A case study related to the role of hyperglycemia in the cause of prediabetes and type 2 diabetes-associated impairment of microvascular function is presented. It also discusses the increased risks of insulin resistance, blood pressure, and lipid profile. It further presents the detailed methodology of conduction of the study and the various statistics associated with it.
- Published
- 2017
- Full Text
- View/download PDF
29. Complement Factor 3 Is Associated With Insulin Resistance and With Incident Type 2 Diabetes Over a 7-Year Follow-up Period: The CODAM Study.
- Author
-
Wlazlo, Nick, van Greevenbroek, Marleen M. J., Ferreira, Isabel, Feskens, Edith J. M., van der Kallen, Carla J. H., Schalkwijk, Casper G., Bravenboer, Bert, and Stehouwer, Coen D. A.
- Subjects
INSULIN resistance ,TYPE 2 diabetes risk factors ,GLUCOSE tolerance tests ,HOMEOSTASIS ,FAT cells ,METABOLIC disorders - Abstract
OBJECTIVE Immune dysregulation can affect insulin resistance (IR) and b-cell function and hence contribute to development of type 2 diabetes mellitus (T2DM). The complement system, as a regulator of immune and in flammatory homeostasis, may be a relevant contributor therein. However, longitudinal studies focusing on complement as a determinant of T2DMand IR are scarce. Therefore, we prospectively investigated the association of plasma complement factor 3 (C3) with (estimates of) IR in muscle, liver, and adipocytes, as well as with glucose tolerance, including incident T2DM. RESEARCH DESIGN AND METHODS Fasting C3, nonesterified fatty acids, glucose, and insulin (the latter two during oral glucose tolerance tests) were measured at baseline (n = 545) and after 7 years of follow-up (n = 394) in a prospective cohort study. RESULTS Over the 7-year period, C3 levels (per 0.1 g/L) were longitudinally associated with higher homeostasis model assessment of IR (HOMA2-IR; β = 15.2%[95% CI 12.9-17.6]), hepatic IR (β = 6.1%[95% CI 4.7-7.4]), adipocyte IR (β = 16.0% [95%CI 13.0-19.1]), fasting glucose (β = 1.8% [95% CI 1.2-2.4]), 2-h glucose (β = 5.2% [95% CI 3.7-6.7]), and area under the curve for glucose (β = 3.6% [95% CI 2.7-4.6]). In addition, greater changes in C3 (per 0.1 g/L) were associated with greater changes in HOMA2-IR (β = 0.08 [95% CI 0.02-0.15]) and greater changes in hepatic IR (β = 0.87 [95% CI 0.12-1.61]) over 7 years, but not glucose tolerance. Moreover, baseline C3 was associated with the 7-year incidence of T2DM (odds ratio 1.5 [95% CI 1.1-2.0]). CONCLUSIONS Changes in C3 were associated with changes in several measures of IR and may reflect progression of metabolic dysregulation, which eventually leads to abnormalities in glucose tolerance and T2DM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
30. Insulin Sensitivity and Albuminuria: The RISC Study.
- Author
-
Pilz, Stefan, Rutters, Femke, Nijpels, Giel, Stehouwer, Coen D. A., Højlund, Kurt, Nolan, John J., Balkau, Beverley, and Dekker, Jacqueline M.
- Subjects
PHYSIOLOGICAL effects of insulin ,ALBUMINURIA ,CARDIOVASCULAR diseases risk factors ,INSULIN resistance ,GLUCOSE tolerance tests - Abstract
OBJECTIVE Accumulating evidence suggests an association between insulin sensitivity and albuminuria, which, even in the normal range, is a risk factor for cardiovascular diseases. We evaluated whether insulin sensitivity is associated with albuminuria in healthy subjects. RESEARCH DESIGN AND METHODS We investigated 1,415 healthy, nondiabetic participants (mean age 43.9 ± 8.3 years; 54.3% women) from the RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) study, of whom 852 participated in a follow-up examination after 3 years. At baseline, insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamps, expressed as the M/I value. Oral glucose tolerance test-based insulin sensitivity (OGIS), homeostasis model assessment of insulin resistance (HOMA-IR), and urinary albumin-to-creatinine ratio (UACR) were determined at baseline and follow-up. RESULTS Microalbuminuria (UACR ≥30mg/g) was present in fewer than 2% at either study visit. After multivariate adjustments, there was no cross-sectional association between UACR and any measure of insulin sensitivity. Neither OGIS nor HOMA-IR was significantly associated with follow-up UACR, but in a multivariate regression analysis, baseline M/I emerged as an independent predictor of UACR at follow-up (β-coefficient -0.14; P =0.001). CONCLUSIONS In healthy middle-aged adults, reduced insulin sensitivity, assessed by hyperinsulinemic-euglycemic clamp, is continuously associated with a greater risk of increasing albuminuria. This finding suggests that reduced insulin sensitivity either is simply related to or might causally contribute to the initial pathogenesis of albuminuria. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study.
- Author
-
van der Heijden, Amber A W A, Van't Riet, Esther, Bot, Sandra D M, Cannegieter, Suzanne C, Stehouwer, Coen D A, Baan, Caroline A, Dekker, Jacqueline M, and Nijpels, Giel
- Abstract
Objective: To investigate risk of a recurrent cardiovascular event and its predictors in a population-based cohort.Research Design and Methods: Participants of the Hoorn Study who had experienced a first cardiovascular event after baseline (n = 336) were followed with respect to a recurrent event. Absolute risk of a recurrent event was calculated for individuals with normal glucose metabolism, intermediate hyperglycemia, and type 2 diabetes. Cox regression models were used to investigate which variables, measured before the first vascular event, predicted a recurrent event using the stepwise backward procedure.Results: During a median follow-up of 4.1 years, 44% (n = 148) of the population developed a recurrent vascular event. The rate of recurrent events per 100 person-years was 7.2 (95% CI 5.8-8.7) in individuals with normal glucose metabolism, compared with 9.8 (6.6-14.0) in individuals with intermediate hyperglycemia and 12.5 (8.5-17.6) in individuals with type 2 diabetes. Higher age (hazard ratio 1.02 [95% CI 1.00-1.04]), male sex (1.56 [1.08-2.25]), waist circumference (1.02 [1.02-1.03]), higher systolic blood pressure (1.01 [1.01-1.02]), higher HbA1c (%, 1.13 [0.97-1.31]/ mmol/mol, 1.01 [1.00-1.03]), and family history of myocardial infarction (1.38 [0.96-2.00]) predicted a recurrent cardiovascular event.Conclusions: Individuals with type 2 diabetes, but not individuals with intermediate hyperglycemia, are at increased risk for a recurrent vascular event compared with individuals with normal glucose metabolism. In people with a history of cardiovascular disease, people at increased risk of a recurrent event can be identified based on the patient's risk profile before the first event. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
32. The 1997 American Diabetes Association Criteria Versus the 1985 World Health Organization Criteria for the Diagnosis of Abnormal Glucose Tolerance: Poor agreement in the Hoorn Study
- Author
-
Vegt, Femmie De, primary, Dekker, Jacqueline M, additional, Stehouwer, Coen D A, additional, Nijpels, Giel, additional, Bouter, Lex M, additional, and Heine, Robert J, additional
- Published
- 1998
- Full Text
- View/download PDF
33. Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht Aging Study.
- Author
-
Spauwen, Peggy J J, Köhler, Sebastian, Verhey, Frans R J, Stehouwer, Coen D A, and van Boxtel, Martin P J
- Abstract
Objective: To examine the effects of baseline and incident diabetes on change in cognitive function over 12 years.Research Design and Methods: A sample of 1,290 individuals aged ≥ 40 years at baseline, participating in the Maastricht Aging Study, were cognitively tested at baseline, after 6 years, and after 12 years. Of these, 68 participants had type 2 diabetes at baseline, and 54 and 57 had incident diabetes at the 6- and 12-year follow-up, respectively. Changes in performance on tests of information-processing speed, executive function, and verbal memory from baseline to 6- and 12-year follow-up were compared between groups using linear mixed models. Effects of diabetes on cognitive decline were adjusted for demographic variables, history of smoking, alcohol intake, and comorbid conditions, including hypertension, cardiovascular disease, BMI, and depression.Results: Participants with baseline diabetes showed larger decline in information-processing speed (estimate -7.64; P < 0.01), executive function (21.82; P < 0.01), and delayed word recall (-1.35; P < 0.05) over the 12-year follow-up compared with control subjects. No significant difference in decline was observed for immediate word recall. Compared with control subjects, participants with incident diabetes showed subtle early decline in information-processing speed only. Interestingly, they did not show larger decline in any other cognitive domain.Conclusions: Individuals with baseline type 2 diabetes show accelerated cognitive decline, particularly in information-processing speed and executive function, compared with individuals without diabetes. In incident diabetes, decline in speed becomes detectable first, and cognitive decline seems to increase with increasing exposure time. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
34. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study.
- Author
-
Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, van der Kallen CJ, Schalkwijk CG, Bravenboer B, Stehouwer CD, Wlazlo, Nick, van Greevenbroek, Marleen M J, Ferreira, Isabel, Jansen, Eugene H J M, Feskens, Edith J M, van der Kallen, Carla J H, Schalkwijk, Casper G, Bravenboer, Bert, and Stehouwer, Coen D A
- Abstract
Objective: Adipocyte insulin resistance (IR) is a key feature early in the pathogenesis of type 2 diabetes mellitus (T2DM), and although scarce, data in the literature suggest a direct role for iron and iron metabolism-related factors in adipose tissue function and metabolism. Serum ferritin and transferrin were shown to be associated with muscle insulin resistance (IR) and T2DM, but little is known about the role of iron metabolism on adipose tissue. We therefore investigated whether markers of iron metabolism were associated with adipocyte IR and plasma adiponectin.Research Design and Methods: Serum ferritin, transferrin, total iron, non-transferrin-bound iron (NTBI), transferrin saturation, and plasma adiponectin were determined in 492 individuals. Adipocyte IR was defined by the product of fasting insulin and nonesterified fatty acids (NEFAs). Using linear regression analyses, we investigated the difference in adipocyte IR or adiponectin (in %) according to differences in iron metabolism markers.Results: Serum ferritin (β = 1.00% increase in adipocyte IR per 10 μg/L [95% CI 0.66-1.34]), transferrin (4.18% per 0.1 g/L [2.88-5.50]), total iron (1.36% per μmol/L [0.61-2.12]), and NTBI (5.14% per μmol/L [1.88-8.52]) were associated with adipocyte IR after adjustment for several covariates, including inflammatory markers. All markers of iron metabolism were also associated with NEFAs (all P < 0.01). In addition, ferritin and transferrin were inversely associated with adiponectin (both P < 0.01).Conclusions: The observed associations of several markers of iron metabolism with adipocyte IR and adiponectin suggest that factors related to iron and iron metabolism may contribute to adipocyte IR early in the pathogenesis of T2DM. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
35. Iron MetabolismIs Associated With Adipocyte Insulin Resistance and Plasma Adiponectin.
- Author
-
WLAZLO, NICK, VAN GREEVENBROEK, MARLEEN M. J., FERREIRA, ISABEL, JANSEN, EUGENE H. J. M., FESKENS, EDITH J. M., VAN DER KALLEN, CARLA J. H., SCHALKWIJK, CASPER G., BRAVENBOER, BERT, and STEHOUWER, COEN D. A.
- Subjects
INSULIN resistance ,TYPE 2 diabetes ,FAT cells ,DIABETES complications ,TRANSFERRIN ,IRON metabolism - Abstract
OBJECTIVE--Adipocyte insulin resistance (IR) is a key feature early in the pathogenesis of type 2 diabetes mellitus (T2DM), and although scarce, data in the literature suggest a direct role for iron and iron metabolism--related factors in adipose tissue function and metabolism. Serum ferritin and transferrin were shown to be associated with muscle insulin resistance (IR) and T2DM, but little is known about the role of iron metabolism on adipose tissue. We therefore investigated whether markers of iron metabolism were associated with adipocyte IR and plasma adiponectin. RESEARCH DESIGN AND METHODS--Serum ferritin, transferrin, total iron, non- transferrin-bound iron (NTBI), transferrin saturation, and plasma adiponectin were determined in 492 individuals. Adipocyte IR was defined by the product of fasting insulin and nonesterified fatty acids (NEFAs). Using linear regression analyses, we investigated the difference in adipocyte IR or adiponectin (in %) according to differences in iron metabolism markers. RESULTS--Serum ferritin (β = 1.00% increase in adipocyte IR per 10 µg/L [95% CI 0.66- 1.34]), transferrin (4.18% per 0.1 g/L [2.88-5.50]), total iron (1.36% per µmol/L [0.61-2.12]), and NTBI (5.14% per µmol/L [1.88-8.52]) were associated with adipocyte IR after adjustment for several covariates, including inflammatory markers. All markers of iron metabolism were also associated with NEFAs (all P <0.01). In addition, ferritin and transferrin were inversely associated with adiponectin (both P <0.01). CONCLUSIONS--The observed associations of several markers of iron metabolism with adipocyte IR and adiponectin suggest that factors related to iron and iron metabolism may contribute to adipocyte IR early in the pathogenesis of T2DM. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study.
- Author
-
Kroon MH, van den Hurk K, Alssema M, Kamp O, Stehouwer CD, Henry RM, Diamant M, Boomsma F, Nijpels G, Paulus WJ, Dekker JM, Kroon, Maria H, van den Hurk, Katja, Alssema, Marjan, Kamp, Otto, Stehouwer, Coen D A, Henry, Ronald M A, Diamant, Michaela, Boomsma, Frans, and Nijpels, Giel
- Abstract
Objective: Heart failure is common in individuals with type 2 diabetes, and early detection of individuals at risk may offer opportunities for prevention. We aimed to explore 1) prospective associations of B-type natriuretic peptide (BNP) levels in a non-heart failure range with changes in markers of left ventricular (LV) function and 2) possible effect modification by type 2 diabetes in a population-based cohort.Research Design and Methods: Echocardiographic measurements were performed at baseline (2000-2001) and follow-up (2007-2009), together with standardized physical examinations and BNP measurements on 300 individuals (mean age 66 years, 32% with type 2 diabetes) of the longitudinal Hoorn Study. Multivariate linear regression analyses were performed to investigate associations of baseline BNP (<100 pg/mL) in individuals without prevalent heart failure at baseline with changes in LV mass index, LV ejection fraction, left atrial volume index, and ratio of early diastolic LV inflow velocity (E) to early diastolic lengthening velocity (e') (E/e').Results: In all individuals, higher BNP was associated with 8-year increases in left atrial volume index. Higher BNP was also associated with increasing LV mass index and E/e'. These associations were significantly stronger in individuals with type 2 diabetes compared with the nonsignificant associations in individuals without type 2 diabetes.Conclusions: This 8-year follow-up study shows that higher BNP levels in a non-heart failure range were associated with an increased LV mass and deteriorated LV diastolic function, particularly in individuals with type 2 diabetes. This implies that the presence or absence of type 2 diabetes should be taken into account if BNP levels are used to assess future heart failure risk. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
37. NH2-Terminal Probrain Natriuretic Peptide Is Associated With Diabetes Complications in the EURODIAB Prospective Complications Study.
- Author
-
Gruden, Gabriella, Barutta, Federica, Chaturvedi, Nish, Schalkwijk, Casper, Stehouwer, Coen D., Pinach, Silvia, Manzo, Maria, Loiacono, Maria, Tricarico, Marinella, Mengozzi, Giulio, Witte, Daniel R., Fuller, John H., Perin, Paolo Cavallo, and Bruno, Graziella
- Subjects
NATRIURETIC peptides ,HEART failure ,CARDIOVASCULAR diseases risk factors ,PEOPLE with diabetes ,DIABETES - Abstract
OBJECTIVE--Circulating levels of NH
2 -terminal probrain natriuretic peptide (NTproBNP), a marker of acute heart failure, are associated with increased risk of cardiovascular disease (CVD) in the general population. However, there is little information on the potential role of NT-proBNP as a biomarker of vascular complications in type 1 diabetic patients. We investigated whether serum NT-proBNP levels were associated with micro- and macrovascular disease in type 1 diabetic subjects. RESEARCH DESIGN AND METHODS--A cross-sectional nested case-control study from the EURODIAB Prospective Complications Study of 507 type 1 diabetic patients was performed. Case subjects (n = 345) were defined as those with one or more complications of diabetes; control subjects (n = 162) were those with no evidence of any complication. We measured NT-proBNP levels by a two-site sandwich electrochemiluminescence immunoassay and investigated their associations with complications. RESULTS--Mean NT-proBNP levels were significantly higher in case than in control subjects. In logistic regression analyses, NT-proBNP values > 26.46 pg/mL were independently associated with a 2.56-fold increased risk of all complications. Odds ratios of CVD (3.95 [95% CI 1.26-- 12.35]), nephropathy (4.38 [1.30--14.76]), and distal symmetrical polyneuropathy (4.32 [1.41-- 13.23]) were significantly increased in patients with NT-proBNP values in the highest quartile (>84.71 pg/mL), independently of renal function and known risk factors. These associations were no longer significant after inclusion of TNF-α into the model. CONCLUSIONS--In this large cohort of type 1 diabetic subjects, we found an association between NT-proBNP and diabetic micro- and macrovascular complications. Our results suggest that the inflammatory cytokine TNF-a may be involved in this association. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
38. Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2 diabetes: nineteen-year follow-up of a population-based cohort study.
- Author
-
Hanssen NM, Huijberts MS, Schalkwijk CG, Nijpels G, Dekker JM, Stehouwer CD, Hanssen, Nordin M J, Huijberts, Maya S, Schalkwijk, Casper G, Nijpels, Giel, Dekker, Jacqueline M, and Stehouwer, Coen D A
- Abstract
Objective: In the general population, a low ankle-brachial index (ABI) (<0.9) is strongly associated with (cardiovascular) mortality. However, the association between the ABI and mortality may be weaker in individuals with diabetes, as ankle pressures may be elevated by medial arterial calcification and arterial stiffening, which occur more frequently in diabetes. Therefore, the aim of this study was to compare the association between ABI and mortality in individuals without and with diabetes.Research Design and Methods: We studied the associations between ABI and cardiovascular and all-cause mortality in 624 individuals from the Hoorn study, a population-based cohort of 50- to 75-year-old individuals (155 with diabetes and 469 without) followed for a median period of 17.2 years. Data were analyzed using Cox proportional hazards models.Results: During the follow-up period, 289 of 624 (46.3%) participants died (97 of 155 with and 192 of 469 without diabetes and 52 of 65 with and 237 of 559 without ABI <0.9): 85 (29.4%) of CVD (30 of 155 with and 55 of 469 without diabetes and 20 of 65 with and 65 of 559 without ABI <0.9). A low ABI was strongly associated with cardiovascular mortality (relative risk 2.57 [95% CI 1.50-4.40]) and all-cause mortality (2.02 [1.47-2.76]), after adjustment for Framingham risk factors. The associations of the ABI with mortality did not differ between individuals without and with diabetes for cardiovascular (P(interaction) = 0.45) or all-cause (P(interaction) = 0.63) mortality.Conclusions: In the Hoorn Study, associations between ABI and cardiovascular and all-cause mortality were similar in individuals without and with diabetes. Future studies should investigate, in both individuals without and with diabetes, whether measurement of ABI can be used to guide treatment decisions. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
39. Exercise therapy in type 2 diabetes: is daily exercise required to optimize glycemic control?
- Author
-
van Dijk JW, Tummers K, Stehouwer CD, Hartgens F, van Loon LJ, van Dijk, Jan-Willem, Tummers, Kyra, Stehouwer, Coen D A, Hartgens, Fred, and van Loon, Luc J C
- Abstract
Objective: Given the transient nature of exercise-induced improvements in insulin sensitivity, it has been speculated that daily exercise is preferred to maximize the benefits of exercise for glycemic control. The current study investigates the impact of daily exercise versus exercise performed every other day on glycemic control in type 2 diabetic patients.Research Design and Methods: Thirty type 2 diabetic patients (age 60 ± 1 years, BMI 30.4 ± 0.7 kg/m(2), and HbA(1c) 7.2 ± 0.2%) participated in a randomized crossover experiment. Subjects were studied on three occasions for 3 days under strict dietary standardization but otherwise free-living conditions. Blood glucose homeostasis was assessed by continuous glucose monitoring over 48 h during which subjects performed no exercise (control) or 60 min of cycling exercise (50% maximal workload capacity) distributed either as a single session performed every other day or as 30 min of exercise performed daily.Results: The prevalence of hyperglycemia (blood glucose >10 mmol/L) was reduced from 7:40 ± 1:00 h:min per day (32 ± 4% of the time) to 5:46 ± 0:58 and 5:51 ± 0:47 h:min per day, representing 24 ± 4 and 24 ± 3% of the time, when exercise was performed either daily or every other day, respectively (P < 0.001 for both treatments). No differences were observed between the impact of daily exercise and exercise performed every other day.Conclusions: A short 30-min session of moderate-intensity endurance-type exercise substantially reduces the prevalence of hyperglycemia throughout the subsequent day in type 2 diabetic patients. When total work is being matched, daily exercise does not further improve daily glycemia compared with exercise performed every other day. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
40. One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney disease.
- Author
-
Alssema M, Newson RS, Bakker SJ, Stehouwer CD, Heymans MW, Nijpels G, Hillege HL, Hofman A, Witteman JC, Gansevoort RT, Dekker JM, Alssema, Marjan, Newson, Rachel S, Bakker, Stephan J L, Stehouwer, Coen D A, Heymans, Martijn W, Nijpels, Giel, Hillege, Hans L, Hofman, Albert, and Witteman, Jacqueline C M
- Abstract
Objective: Individuals at high risk for chronic cardiometabolic disease (cardiovascular disease [CVD], type 2 diabetes, and chronic kidney disease [CKD]) share many risk factors and would benefit from early intervention. We developed a nonlaboratory-based risk-assessment tool for identification of people at high cardiometabolic disease risk.Research Design and Methods: Data of three population-based cohorts from different regions of the Netherlands were merged. Participants were 2,840 men and 3,940 women, white, aged 28-85 years, free from CVD, type 2 diabetes, and CKD diagnosis at baseline. The outcome was developing cardiometabolic disease during 7 years follow-up.Results: Age, BMI, waist circumference, antihypertensive treatment, smoking, family history of myocardial infarction or stroke, and family history of diabetes were significant predictors, whereas former smoking, history of gestational diabetes, and use of lipid-lowering medication were not. The models showed acceptable calibration (Hosmer and Lemeshow statistics, P > 0.05) and discrimination (area under the receiver operating characteristic [ROC] curve 0.82 [95% CI 0.81-0.83] for women and 0.80 [0.78-0.82] for men). Discrimination of individual outcomes was lowest for diabetes (area under the ROC curve 0.70 for men and 0.73 for women) and highest for CVD mortality (0.83 for men and 0.85 for women).Conclusions: We demonstrate that a single risk stratification tool can identify people at high risk for future CVD, type 2 diabetes, and/or CKD. The present risk-assessment tool can be used for referring the highest risk individuals to health care for further (multivariable) risk assessment and may as such serve as an important part of prevention programs targeting chronic cardiometabolic disease. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
41. Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria.
- Author
-
Persson, Frederik, Rossing, Peter, Reinhard, Henrik, Juhl, Tina, Stehouwer, Coen D. A., Schalkwijk, Casper, Danser, A. H. Jan, Boomsma, Frans, Frandsen, Erik, and Parving, Hans-Henrik
- Subjects
IRBESARTAN ,TYPE 2 diabetes ,HYPERTENSION ,ALBUMINURIA ,COMORBIDITY ,COMBINATION drug therapy ,DRUG side effects - Abstract
OBJECTIVE -- We investigated whether the antiproteinuric effect of the direct renin inhibitor aliskiren is comparable to that of irbesartan and the effect of the combination. RESEARCH DESIGN AND METHODS -- This was a double-blind, randomized, cross-over trial. After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (> 100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses. Patients received furosemide in a stable dose throughout the study. The primary end point was a change in albuminuria. Secondary measures included change in 24-h blood pressure and glomerular filtration rate (GFR). RESULTS -- Placebo geometric mean albuminuria was 258 mg/day (range 84-2,361), mean ± SD 24-h blood pressure was 140/73 ± 15/8 mmHg, and GFR was 89 ± 27 ml/min per 1.73 m
2 ;. Aliskiren treatment reduced albuminuria by 48% (95% CI 27-62) compared with placebo (P < 0.001), not significantly different from the 58% (42-79) reduction with irbesartan treatment (P < 0.001 vs. placebo). Combination treatment reduced albuminuria by 71% (59-79), more than either monotherapy (P < 0.001 and P = 0.028). Fractional clearances of albumin were significantly reduced (46, 56, and 67% reduction vs. placebo). Twenty-four-hour blood pressure was reduced 3/4 mmHg by aliskiren (NS/P = 0.009), 12/5 mmHg by irbesartan (P < 0.001/P = 0.002), and 10/6 mmHg by the combination (P = 0.001/P < 0.001). GFR was significantly reduced 4.6 (95% CI 0.3-8.8) ml/min per 1.73 m2 by aliskiren, 8.0 (3.6-12.3) ml/min per 1.73 m2 by irbesartan, and 11.7 (7.4-15.9) ml/min per 1.73 m2 by the combination. CONCLUSIONS -- The combination of aliskiren and irbesartan is more antiproteinuric in type 2 diabetic patients with albuminuria than monotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
42. Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study.
- Author
-
Beijers HJ, Ferreira I, Bravenboer B, Dekker JM, Nijpels G, Heine RJ, Stehouwer CD, Beijers, Hanneke J B H, Ferreira, Isabel, Bravenboer, Bert, Dekker, Jacqueline M, Nijpels, Giel, Heine, Robert J, and Stehouwer, Coen D A
- Abstract
Objective: Microalbuminuria is associated with cardiovascular mortality, particularly among individuals with type 2 diabetes, but the mechanisms underlying this association are not completely understood. Microalbuminuria is known to be associated with cardiovascular autonomic dysfunction (C-AD), and C-AD in turn is associated with cardiovascular mortality. The purpose of this study, therefore, was to investigate whether C-AD can explain the relationship between microalbuminuria and cardiovascular mortality.Research Design and Methods: We studied 490 individuals from a population-based cohort of individuals aged 50-75 years who were followed for a median period of 13.6 years. Microalbuminuria was defined as an albumin-to-creatinine ratio > or =2.0 mg/mmol in an early-morning spot-urine sample. Ten parameters reflecting different aspects of cardiovascular autonomic function were measured and compiled into a total score of C-AD (mean of separate z scores). The association between C-AD and microalbuminuria was estimated by multiple linear regression, and relative risks (RRs) for cardiovascular mortality were estimated by Cox proportional hazards analyses.Results: After adjustments for age, sex, glucose tolerance status, and other risk factors, C-AD was associated with microalbuminuria (beta = 0.16 [95% CI 0.01-0.33]), and both microalbuminuria (RR 2.09 [1.07-4.08]) and C-AD (1.74 [1.04-2.89]) were associated with cardiovascular mortality. These associations did not change after further mutual adjustment for C-AD (2.13 [1.09-4.17]) or microalbuminuria (1.76 [1.05-2.94]), respectively.Conclusions: Both microalbuminuria and C-AD are independently associated with cardiovascular mortality, and the excess mortality attributable to microalbuminuria cannot be explained by C-AD. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
43. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria.
- Author
-
Hyvärinen M, Qiao Q, Tuomilehto J, Laatikainen T, Heine RJ, Stehouwer CD, Alberti KG, Pyörälä K, Zethelius B, Stegmayr B, DECODE Study Group, Hyvärinen, Marjukka, Qiao, Qing, Tuomilehto, Jaakko, Laatikainen, Tiina, Heine, Robert J, Stehouwer, Coen D A, Alberti, K George M M, Pyörälä, Kalevi, and Zethelius, Björn
- Abstract
Objective: We investigated stroke mortality in individuals in different categories of glycemia and compared hazard ratios (HRs) corresponding to a 1-SD increase in 2-h plasma glucose and fasting plasma glucose (FPG) criteria.Research Design and Methods: We examined data from 2-h 75-g oral glucose tolerance tests taken from 13 European cohorts comprising 11,844 (55%) men and 9,862 (45%) women who were followed up for a median of 10.5 years. A multivariate adjusted Cox proportional hazards model was used to estimate HRs for stroke mortality.Results: In men and women without a prior history of diabetes, multivariate adjusted HRs for stroke mortality corresponding to a 1-SD increase in FPG were 1.02 (95% CI 0.83-1.25) and 1.52 (1.22-1.88) and those in 2-h plasma glucose 1.21 (1.06-1.38) and 1.31 (1.06-1.61), respectively. Addition of 2-h plasma glucose to the model with FPG significantly improved prediction of stroke mortality in men (chi2 = 10.12; P = 0.001) but not in women (chi2 = 0.01; P = 0.94), whereas addition of FPG to 2-h plasma glucose improved stroke mortality in women (chi2 = 4.08; P = 0.04) but not in men (chi2 = 3.29; P = 0.07).Conclusions: Diabetes defined by either FPG or 2-h plasma glucose increases the risk of stroke mortality. In individuals without a history of diabetes, elevated 2-h postchallenge glucose is a better predictor than elevated fasting glucose in men, whereas the latter is better than the former in women. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
44. Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years.
- Author
-
Astrup, Anne Sofie, Tarnow, Lise, Pietraszek, Lotte, Schalkwijk, Casper G., Stehouwer, Coen D. A., Parving, Hans-Henrik, and Rossing, Peter
- Subjects
BIOMARKERS ,ENDOTHELIUM diseases ,INFLAMMATION ,PEOPLE with diabetes ,DIABETIC nephropathies ,MORTALITY ,GLOMERULAR filtration rate - Abstract
OBJECTIVE -- We evaluated the association of biomarkers of endothelial dysfunction and inflammation with all-cause mortality and cardiovascular mortality and morbidity and decline in glomerular filtration rate (GFR) in type 1 diabetic patients. RESEARCH DESIGN AND METHODS -- We prospectively followed 199 type 1 diabetic patients with diabetic nephropathy and 192 patients with persistent normoalbuminuria. Biomarkers were measured at baseline. RESULTS -- We constructed two Z scores: the mean inflammatory Z score combined C-reactive protein, interleukin-6, soluble intercellular adhesion molecule (sICAM-1), and secreted phospholipase A2 and the mean Z score for endothelial dysfunction combined soluble vascular cell adhesion molecule 1, plasminogen activator inhibitor-1, and sICAM-1. The mean Z score of inflammatory biomarkers was associated with mortality and the combined end point in patients with diabetic nephropathy after multivariate adjustment (hazard ratio 1.7 [95% CI 1.1-2.6]; P = 0.025 and 1.5 [1.1-2.21; P = 0.017). The mean Z score for endothelial dysfunction biomarkers was associated with mortality in a model adjusting for age and sex in patients with diabetic nephropathy (1.6 [1.0-2.3]; P = 0.031). The mean Z score for endothelial dysfunction correlated with decline in GFR (r = -0.243; P = 0.001); the correlation persisted after multivariate adjustment (coefficient -1.38 [95% CI -2.27 to -0.50]; P = 0.002). CONCLUSIONS -- Mean Z scores of inflammatory biomarkers are significantly associated with all-cause mortality and cardiovascular morbidity and mortality in patients with nephropathy after multivariate adjustment. These data suggest that the high risk of cardiovascular disease in type 1 diabetes may be explained in part by inflammatory activity. Mean Z score of endothelial dysfunction correlated after multivariate adjustment with the rate of decline in GFR. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
45. High Risk of Cardiovascular Mortality in Individuals With Impaired Fasting Glucose Is Explained by Conversion to Diabetes.
- Author
-
Rijkelijkhuizen, Josina M., Nijpels, Giel, Heine, Robert J., Bouter, Lex M., Stehouwer, Coen D. A., and Dekker, Jacqueline M.
- Subjects
DIABETES ,TYPE 2 diabetes ,CARDIOVASCULAR disease related mortality ,GLUCOSE ,DISEASE risk factors - Abstract
OBJECTIVE -- To optimize identification of future diabetic patients, the American Diabetes Association (ADA) introduced criteria for impaired fasting glucose (IFG) in 1997 (IFG 6.1 mmol/l [IFG6.1]) and lowered the threshold from 6.1 to 5.6 mmol/l (IFG5.6) in 2003. Our aim was to assess the consequences of lowering the IFG cutoff on the risk of cardiovascular disease (CVD) mortality and to evaluate whether this risk is explained by a conversion to type 2 diabetes within 6.4 years. RESEARCH DESIGN AND METHODS -- In a population-based cohort, the Hoorn Study, plasma glucose was determined in 1989 and 1996 (n = 1,428). Subjects were classified in 1.989 according to 1997 and 2003 ADA criteria. Subjects with IFG in 1989 were further classified according to diabetes status in 1996. Hazard ratios for CVD mortality (n = 81) in the period 1996-2005 were adjusted for age and sex. RESULTS -- Subjects with IFG6.1, but not IFG5.6, had a significantly higher CVD mortality risk than normal fasting glucose (NFG) subjects. Subjects who converted from IFG to diabetes (IFG6.1: 42%; IFG5.6: 21%) had a more than twofold risk of CVD mortality (IFG6.1: 2.47 [1.17-5.19]; IFGS.6: 2.14 [1.12-4.10]) than subjects with NFG. IFG subjects who did not develop diabetes did not have significantly higher CVD mortality risks (IFG6.1: 1.50 [0.72-3.151; IFGS.6: 1.15 [0.69-1.93]). CONCLUSIONS -- The lower cutoff for IFG (ADA 2003 criteria) results in a category of IFG that no longer represents a high-risk state of CVD. Furthermore, only subjects who convert from IFG to diabetes have a high risk of CVD mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
46. Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women.
- Author
-
Snijder, Marieke B., Heine, Robert J., Seidell, Jacob C., Bouter, Lex M., Stehouwer, Coen D. A., Nijpels, Giel, Funahashi, Tohru, Matsuzawa, Yuji, Shimomura, Iichiro, and Dekker, Jacqueline M.
- Subjects
BLOOD sugar ,TYPE 2 diabetes ,OBESITY ,METABOLISM ,DIABETES - Abstract
OBJECTIVE -- Adiponectin is an adipose tissue-derived protein. Low levels are associated with obesity, insulin resistance, and type 2 diabetes. Our objective was to investigate the prospective association between adiponectin levels and the 6.4-year risk of type 2 diabetes and of impaired glucose metabolism (IGM). RESEARCH DESIGN AND METHODS -- The Hoorn Study is a cohort study among Caucasians, aged 50-75 years. BMI, waist-to-hip ratio (WHR), fasting glucose, 2-h glucose, triglycerides, HDL cholesterol, LDL cholesterol, alanine aminotransferase, leptin, and adiponectin were measured at baseline. Lifestyle (alcohol intake, smoking, and physical activity) was assessed by questionnaires. After a mean follow-up of 6.4 years, glucose tolerance was assessed by a 75-g oral glucose tolerance test. Analyses were performed in 1,264 subjects (584 men and 680 women) without type 2 diabetes at baseline. For analyses of incident IGM, 239 subjects with IGM at baseline and/or type 2 diabetes at follow-up were excluded. RESULTS -- Age- and lifestyle-adjusted odds ratios and 95% CIs comparing highest with lowest adiponectin quartile were 0.52 (0.23-1.18) in men and 0.15 (0.06-0.39) in women for type 2 diabetes and 0.90 (0.51-1.61) and 0.28 (0.16-0.48) for IGM, respectively. The risks were only slightly reduced after adjustment for WHR and leptin as markers of (abdominal) adiposity. Adjustment for baseline fasting and postload glucose levels (potential mediators) substantially diminished these inverse associations with type 2 diabetes (0.79 [0.32-1.91] and 0.62 [0.21-1.81]) and with IGM (1.20 [0.61-2.35] and 0.48 [0.26-0.90]), respectively. CONCLUSIONS -- A high adiponectin level was strongly associated with a lower risk of IGM and type 2 diabetes, particularly in women. These results suggest that adiponectin is involved in the pathophysiology linking obesity to type 2 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
47. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study.
- Author
-
van Hecke MV, Dekker JM, Stehouwer CDA, Polak BCP, Fuller JH, Sjolie AK, Kofinis A, Rottiers R, Porta M, Chaturvedi N, van Hecke, Manon V, Dekker, Jacqueline M, Stehouwer, Coen D A, Polak, Bettine C P, Fuller, John H, Sjolie, Anne Katrin, Kofinis, Athanasios, Rottiers, Raoul, Porta, Massimo, and Chaturvedi, Nish
- Abstract
Objective: To study the relationship of nonproliferative and proliferative retinopathy with all-cause mortality and cardiovascular disease (CVD) incidence in type 1 diabetic patients and, additionally, the role of cardiovascular risk factors in these associations.Research Design and Methods: This prospective study included 2,237 type 1 diabetic patients from 31 centers in 16 European countries at baseline, aged 15-60 years, who were examined for retinopathy by taking two-field 45 degrees fundus photographs, which were centrally graded. Mortality and cardiovascular morbidity follow-up was assessed 6-8 years after baseline examination according to a standardized protocol.Results: After 7.9 years of follow-up, 64 patients had died and 128 patients had incident CVD. The age- and sex-adjusted hazard ratios (HRs) of all-cause mortality were 1.45 (95% CI 0.71-2.96) and 4.16 (1.96-8.84) in patients with nonproliferative and proliferative retinopathy at baseline, respectively. Adjustments for cardiovascular risk factors completely obliterated the association with nonproliferative retinopathy, whereas the association with proliferative retinopathy remained twofold increased, although nonsignificant. The age- and sex-adjusted HRs of incident CVD were 1.73 (1.15-2.60) and 2.05 (1.22-3.45) in patients with nonproliferative and proliferative retinopathy, respectively. After adjustments for cardiovascular risk factors, both associations were attenuated and lost statistical significance.Conclusions: This study shows that type 1 diabetic patients with nonproliferative or proliferative retinopathy have an increased risk for all-cause mortality and incident CVD. The presence of cardiovascular risk factors explained the associations to a large extent, except for the associations with proliferative retinopathy, which suggests that other shared mechanisms may be involved. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
48. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study.
- Author
-
Alssema M, Dekker JM, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ, Alssema, Marjan, Dekker, Jacqueline M, Nijpels, Giel, Stehouwer, Coen D A, Bouter, Lex M, Heine, Robert J, and Hoorn Study
- Abstract
Objective: High proinsulin concentration may be a better predictor for cardiovascular disease (CVD) mortality than insulin concentration. Previous observations may have been confounded by glucose tolerance status or lack of precision because of high intraindividual variability. We investigated the longitudinal relation of means of duplicate measurements of insulin and proinsulin with all-cause and CVD mortality in a population-based cohort taking glucose tolerance status into account.Research Design and Methods: Fasting and post-75-g glucose-load (2-h) glucose, insulin, and proinsulin values were determined in duplicate on separate days in 277 participants with normal glucose metabolism, 208 participants with impaired glucose metabolism, and 119 newly detected patients with type 2 diabetes of the Hoorn Study. Insulin resistance and beta-cell function were estimated by homeostasis model assessment (HOMA-IR and HOMA-B, respectively), and the fasting proinsulin-to-insulin ratio was calculated. Subjects were followed with respect to mortality until January 2003.Results: Fasting proinsulin levels were significantly associated with all-cause and CVD mortality. The hazard ratios (HRs) per increase in interquartile range adjusted for age and sex were 1.21 (95% CI 1.04-1.42) for all-cause mortality and 1.33 (1.06-1.66) for CVD mortality. Adjustment for glucose tolerance status and HOMA-IR did not substantially change the associations.Conclusions: Fasting proinsulin was associated with all-cause and CVD mortality, independent of glucose tolerance status and insulin resistance and largely independent of other CVD risk factors. Proinsulin might play a role in the relationship between insulin resistance and CVD. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
49. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.
- Author
-
Tarnow, Lise, Hovind, Peter, Teerlink, Tom, Stehouwer, Coen D. A., and Parving, Hans-Henrik
- Subjects
BLOOD plasma ,NITRIC oxide ,ENDOTHELIUM ,CHRONIC kidney failure ,CARDIOVASCULAR diseases ,PEOPLE with diabetes ,INSULIN ,KIDNEY diseases ,MORTALITY - Abstract
Objective: Increased plasma concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, has been associated with endothelial dysfunction, insulin resistance, and atherosclerosis in nondiabetic populations. In end-stage renal failure, circulating ADMA is elevated and a strong predictor of cardiovascular outcome. This study investigated the relation between ADMA and diabetic micro- and macrovascular complications in a large cohort of type 1 diabetic patients with and without early diabetic nephropathy.Research Design and Methods: ADMA concentrations in plasma were determined by a high-performance liquid chromatography method in 408 type 1 diabetic patients with overt diabetic nephropathy (252 men; mean age 42.7 years [SD 11.0], mean duration of diabetes 28 years [SD 9], median serum creatinine level 102 micromol/l [range 52-684]). A group of 192 patients with longstanding type 1 diabetes and persistent normoalbuminuria served as control subjects (118 men; mean age 42.6 years [SD 10.2], mean duration of diabetes 27 years [SD 9]).Results: In patients with diabetic nephropathy, mean +/- SD plasma ADMA concentration was elevated 0.46 +/- 0.08 vs. 0.40 +/- 0.08 micromol/l in normoalbuminuric patients (P<0.001). An increase in plasma ADMA of 0.1 micromol/l increased the odds ratio of nephropathy to 2.77 (95% CI 1.89-4.05) (P<0.001). Circulating ADMA increased in nephropathy patients with declining kidney function, as indicated by elevated values in the lower quartiles of glomerular filtration rate (<76 ml.min(-1).1.73 m(-2)) (P<0.001 ANOVA). Mean ADMA levels were similar in patients with or without diabetic retinopathy (P>0.2). However, in 44 patients with nephropathy and history of myocardial infarction and/or stroke, ADMA was significantly elevated at 0.48 +/- 0.08 micromol/l compared with 0.46 +/- 0.08 micromol/l in patients without major cardiovascular events (P=0.05).Conclusions: Elevated circulating ADMA may contribute to the excess cardiovascular morbidity and mortality in early diabetic nephropathy. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
50. Left ventricular mass increases with deteriorating glucose tolerance, especially in women: independence of increased arterial stiffness or decreased flow-mediated dilation: the Hoorn study.
- Author
-
Henry RMA, Kamp O, Kostense PJ, Spijkerman AMW, Dekker JM, van Eijck R, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA, Henry, Ronald M A, Kamp, Otto, Kostense, Piet J, Spijkerman, Annemieke M W, Dekker, Jacqueline M, van Eijck, Rosemarie, Nijpels, Giel, Heine, Robert J, Bouter, Lex M, and Stehouwer, Coen D A
- Abstract
Objective: Type 2 diabetes and impaired glucose metabolism (IGM) are associated with an increased cardiovascular disease (CVD) risk. Increased left ventricular mass (LVM) is thought to increase CVD risk through several unfavorable cardiac changes. Type 2 diabetes and IGM are associated with increased LVM, but the underlying mechanism is unclear. We investigated the association between glucose tolerance status (GTS) and LVM and explored whether any such association could be mediated through increased arterial stiffness, impaired endothelial function, or the presence of atherosclerosis.Research Design and Methods: We used ultrasound to measure LVM, carotid and femoral stiffness, carotid-femoral transit time, and flow-mediated vasodilation (FMD) and tonometry to estimate compliance and augmentation index. The study population (n = 780) consisted of 287 individuals with normal glucose metabolism (NGM), 179 with IGM, and 314 with type 2 diabetes, and the mean age was 68.4 years.Results: In women, after adjusting for age, height, BMI, and mean arterial pressure, LVM increased significantly with deteriorating GTS (LVM 157 g in NGM, 155 g in IGM, and 169 g in type 2 diabetes; P for trend <0.018). Additional adjustment for arterial stiffness, FMD, or the presence of atherosclerosis did not materially alter the results, even though these variables were significantly associated with both GTS and LVM. Indexes of hyperglycemia/-insulinemia or insulin resistance explained at most 7% of the association between GTS and LVM. In men, no statistically significant associations were observed.Conclusions: Our data expand the conceptual view of the pathogenesis of GTS-related changes in LVM because we show that the increase in LVM in women is independent of increased arterial stiffness, impaired FMD, or the presence of atherosclerosis. In addition, we show that this increase in LVM is only minimally explained by indexes of hyperglycemia/-insulinemia or insulin resistance. Our data may, in part, explain the increased CVD risk seen in women with deteriorating GTS. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.